REDWOOD CITY, Calif., Aug. 31, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) a clinical development-stage biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced that Paul J. Hastings, Chairman and Chief Executive Officer, will provide a corporate update at two upcoming investor conferences.
- 2016 Wells Fargo Healthcare Conference
OncoMed's corporate presentation is scheduled for 2:55 pm ET on September 8, 2016 in Boston, MA.
- Leerink Partners Roundtable Series: Rare Diseases and Immuno-Oncology
Paul Hastings will provide a fireside chat on Thursday, September 29 at 1:30 pm ET in New York City.
A live webcast of each presentation will be available through the OncoMed website in the Investor Relations section. The webcast will also be archived and available for replay for up to 45 days.
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics. OncoMed has seven anti-cancer therapeutic candidates in clinical development, including demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), brontictuzumab (anti-Notch1, OMP-52M51), anti-DLL4/VEGF bispecific antibody (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), ipafricept (FZD8-Fc, OMP-54F28), and anti-RSPO3 (OMP-131R10), which each target key cancer stem cell signaling pathways including Notch, Wnt and R-spondin LGR. OncoMed is advancing its wholly owned GITRL-Fc candidate and an undisclosed immuno-oncology candidate (IO#2) toward clinical trials in the 2016-2017 timeframe. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK).
Additional information can be found at the company's website:
Media & Investors
Senior Director, Investor Relations and Corporate Communications